Spike Protein News and Research

RSS

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

The group identified a single class of antibodies that target a particular epitope on the RBD of SARS-CoV-2, suggesting that the human polyclonal response to SARS-CoV-2 infection is dominated by a worryingly narrow range of antibodies that target an epitope undergoing rapid mutation.

22 Mar 2021

SARS-CoV-2 infection is circadian

An international team of researchers has found that angiotensin-converting enzyme 2 (ACE2) levels in lung cells vary over the day, affecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The virus entry and replication in the lung cells also have a rhythmic cycle, suggesting circadian processes can affect the virus's life cycle.

22 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Anti-androgen drugs may help disarm coronavirus spike protein, stop progression of COVID-19

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Researchers develop new method for measuring immunity to coronavirus

Igor Stagljar made his career building molecular tools to combat cancer. But when the pandemic hit last March, he aimed his expertise at a new adversary, SARS-CoV-2.

22 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021

N-terminal domain antibodies play a key role in COVID immunity

Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.

19 Mar 2021

Study shows how ACE2 mutations influence SARS-CoV-2 spike binding in humans and animals

Researchers at the University of Wisconsin–Madison aimed to better understand how SARS-CoV-2 interacts with various mammalian angiotensin-converting enzyme 2 (ACE2) receptors. This way, they can identify the factors that influence intra- and cross-species virus transmission.

18 Mar 2021

Scientists explore structure of SARS-CoV-2 receptor-binding domain with G485R mutation

Researchers at the Bio21 Institute and Department of Biochemistry and Pharmacology, The University of Melbourne, studied the structure of a SARS-CoV-2 spike receptor-binding domain (RBD) with a G485R mutation. This mutation is a residue and not directly involved in interactions with the angiotensin-converting enzyme 2 (ACE2) residues but found in the Β1´/Β2' loop region.

18 Mar 2021

SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion

A recent study found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding domains (RBDs) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein similar to the B.1.351 and P.1 variants.

18 Mar 2021

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.

From Aptamer Group 18 Mar 2021

The role of S-acylation in the enhancement of SARS-CoV-2 infectivity

A new study published on the bioRxiv server focuses on the role of S-acylation in the SARS-CoV-2 infection cycle. It has also characterized Spike acylation and has also identified other acylated viral proteins and host enzymes involved in the process of infection. Further, it has also revealed the importance of acylation in viral biogenesis and infection.

18 Mar 2021

Spike Protein News and Research

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

SARS-CoV-2 infection is circadian

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Anti-androgen drugs may help disarm coronavirus spike protein, stop progression of COVID-19

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Researchers develop new method for measuring immunity to coronavirus

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

Developing a COVID-19 vaccine using inactivated E. coli

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

N-terminal domain antibodies play a key role in COVID immunity

Study shows how ACE2 mutations influence SARS-CoV-2 spike binding in humans and animals

Scientists explore structure of SARS-CoV-2 receptor-binding domain with G485R mutation

SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

The role of S-acylation in the enhancement of SARS-CoV-2 infectivity

Study shows how coronavirus variants spread more quickly

Quantum dot-based affinity biosensors in microfluidic systems offer an alternative SARS-CoV-2 diagnostics platform

New research proposes innovative antibody-based treatment to prevent SARS-CoV-2 viral entry

Compromised immunity can allow SARS-CoV-2 to evade the immune system

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News